Key Details
Price
$18.06Annual Revenue
$4.15 BAnnual EPS
-$0.74Annual ROE
-3.71%Beta
0.92Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with BLCO included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Bausch + Lomb Corporation (NYSE:BLCO) will hold its Q3 2024 Results Conference Call on October 30, 2024, at 8:00 AM ET. The call will feature company representatives, including George Gadkowski, Brenton Saunders, and Osama Eldessouky, along with analysts from various financial institutions. Please be aware that this event is being recorded.
Bausch + Lomb (BLCO) reported quarterly earnings of $0.17 per share, which is higher than the Zacks Consensus Estimate of $0.16 per share. This is a decrease compared to earnings of $0.22 per share from the same period last year.
The day was very busy and full of activities for the company.
This week, the Federal Reserve lowered interest rates by 50 basis points, which led to an increase in stock prices in the technology, construction, industrial, machinery, and financial sectors.
Bausch + Lomb (BLCO) saw an increase in its share price during the last trading session, with higher-than-normal trading volume. However, the recent changes in earnings estimates for the stock do not indicate that this upward trend will continue in the future.
The Financial Times has reported that Bausch + Lomb is discussing the possibility of selling itself with advisors. Previously, the company had tried to separate from its parent company, Bausch Health, through a stock-for-stock transaction.
Bausch + Lomb (BLCO) shares rose on Monday after news emerged that the eyecare company is thinking about selling itself.
Bausch + Lomb (BLCO) reported quarterly earnings of $0.13 per share, matching the Zacks Consensus Estimate. This is a decrease from earnings of $0.18 per share from the same period last year.
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from.
FAQ
- What is the primary business of Bausch Lomb?
- What is the ticker symbol for Bausch Lomb?
- Does Bausch Lomb pay dividends?
- What sector is Bausch Lomb in?
- What industry is Bausch Lomb in?
- What country is Bausch Lomb based in?
- When did Bausch Lomb go public?
- Is Bausch Lomb in the S&P 500?
- Is Bausch Lomb in the NASDAQ 100?
- Is Bausch Lomb in the Dow Jones?
- When was Bausch Lomb's last earnings report?
- When does Bausch Lomb report earnings?
- Should I buy Bausch Lomb stock now?